Results 91 to 100 of about 1,653 (153)

Metastasis-Directed Stereotactic Body Radiotherapy in Prostate Cancer Patients Treated with Systemic Therapy and Undergoing Oligoprogression: Report on 11 Consecutive Cases

Radiation
Background: Stereotactic body radiotherapy (SBRT) targeted at metastatic sites of disease progression is emerging as a potential therapeutic approach for managing oligoprogressive prostate cancer. However, a definitive benefit has yet to be demonstrated.
Emanuele Chioccola, Mara Caroprese, Christina A. Goodyear, Angela Barillaro, Caterina Oliviero, Stefania Clemente, Chiara Feoli, Luigi Formisano, Antonio Farella, Laura Cella, Manuel Conson, Roberto Pacelli   +11 more
doaj   +1 more source

Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer

Background: About 15–20 % of patients with metastatic breast cancer (mBC) can experience oligoprogressive disease (OPD) in ≤ 5 sites of disease. Patients with OPD may benefit from metastasis-directed stereotactic radiotherapy (SBRT) to all sites of ...
Carnevale Schianca, Ambra, Giordano, Elisa, Leonardi, Maria Cristina, Santoro, Celeste, Curigliano, Giuseppe, Battaiotto, Elena, Dellapasqua, Silvia, Criscitiello, Carmen, Jereczek-Fossa, Barbara Alicja, Munzone, Elisabetta, Bianco, Nadia, Valenza, Carmine, Trapani, Dario, Milano, Monica, Taurelli Salimbeni, Beatrice, Ferrari, Annamaria, Colleoni, Marco, Dicuonzo, Samantha, Castellano, Grazia, Gandini, Sara, Katrini, Jalissa   +20 more
core   +1 more source

The Role of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Renal Cell Carcinoma (RCC) Treated with ICIs–TKIs: A Retrospective Multicentric Study

Background: This multicentric, retrospective study investigated the use of stereotactic body radiotherapy (SBRT) in patients (pts) with metastatic renal cell carcinoma (mRCC) who experienced oligoprogression during a combination therapy with an immune ...
Tiziana Bruno, Ivan Fazio, Manuela Federico, Leonarda La Paglia, Antonella Mazzonello, Lorella Testa, Valentina Zagardo, Maria La Vecchia, Dario Aiello   +8 more
core   +1 more source

Stereotactic Body Radiation Therapy for Oligoprogressive Disease in Androgen-Suppressed Prostate Cancer: Primary Endpoint Analysis of the TRAP Trial.

PURPOSE: Optimal management of oligoprogressive prostate cancer while on androgen receptor pathway inhibitors (ARPIs) is not known. The TRAP trial tests the role of stereotactic body radiation therapy (SBRT) in this setting. The objective of this phase 2
Dreibe, S, Cole, A, Mullassery, V, Pathmanathan, A, Wylie, J, Murray, J, Parker, C, Palaniappan, N, Guevara, J, Reid, A, McDonald, F, Tirona, A, Tree, AC, Tunariu, N, Attard, G, Diez, P, Suh, Y-E, Frew, J, van As, NJ, Levine, D, Syndikus, I, Patel, P, Tran, A   +22 more
core   +1 more source

Local ablative treatment and continuation of systemic therapy for oligoprogressive metastatic breast cancer: a retrospective cohort study

Cancer Treatment and Research Communications
Introduction: Patients with metastatic breast cancer (MBC) typically receive palliative systemic therapy until unmanageable toxicity or progression, at which point treatment is changed.
Cornelia A.M. Almekinders, Tess I.M. Snellen, Annemiek van Ommen-Nijhof, Tessa G. Steenbruggen, Elisabeth G. Klompenhouwer, Niels F.M. Kok, Koert F.D. Kuhlmann, Frederieke van Duijnhoven, Monique E.M.M. Bos, Terry G. Wiersma, Vincent O. Dezentjé, Gabe S. Sonke   +11 more
doaj   +1 more source

Does a peer review group consensus process for MR-Linac patients affect clinical care? Evaluation of impact and feasibility

Clinical and Translational Radiation Oncology
Background and purpose: Peer review is an important component of quality assurance in radiotherapy. To our knowledge, there are no studies reporting on the feasibility and outcomes of the peer review process for magnetic resonance (MR) guided ...
Yew Sin, Vikneswary Batumalai, Jeremy de Leon, Eugene Leong, Kasri Rahim, Farshad Kasraei, Charles Tran, Tommy Liang, Katrina Biggerstaff, Michael G. Jameson, Nicole Hug, Kathryn Hird, Hendrick Tan   +12 more
doaj   +1 more source

Stereotactic Ablative Body Radiotherapy for Oligoprogressive Estrogen Receptor–Positive Breast Cancer (TROG 20.03 AVATAR): A Phase II Prospective Multicenter Trial

PURPOSE AVATAR (trial registration: ACTRN 12620001212943) is a multicenter phase II single-arm trial to evaluate whether stereotactic ablative body radiotherapy (SABR) for oligoprogressive estrogen receptor (ER)–positive human epidermal ...
Hanna, GG, Morton, C, Siva, S, Tan, J, David, S, Bressel, M, Alomran, R, Yip, E, White, M, Connolly, E   +9 more
core   +1 more source

Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer

Up to 80% of patients under immune checkpoint inhibitors (ICI) face resistance. In this context, stereotactic ablative radiotherapy (SABR) can induce an immune or abscopal response. However, its molecular determinants remain unknown.
María Garrido-Barros, Antonio Rueda-Domínguez, Isabel Barragán, Andrea González-Hernández, Rodolfo Chicas-Sett, Juan Luis Onieva, Alicia Román, Beatriz Martínez-Gálvez, Andrés Vera, Javier Oliver, Juan Zafra, Rafael Ordóñez-Marmolejo, José Carlos Benítez, Elisabeth Pérez-Ruiz, Andrés Mesas   +14 more
core   +1 more source

Comparison of Post-Resistance Treatment Outcomes in EGFR-Mutated NSCLC Patients Following Third-Generation EGFR-TKI Therapy: A Retrospective Cohort Study

Technology in Cancer Research & Treatment
Background Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become the first-line treatment for non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations. The optimal treatment strategy after resistance
Xinyue Li, Kaibo Ding, Dujiang Liu, Ruiqi Song, Zhongsheng Peng, Yanjun Xu, Yi Lu   +6 more
doaj   +1 more source

Oligoprogressive Solitary Bone Metastasis from Follicular Thyroid Carcinoma Managed with Partial Scapulectomy

Follicular thyroid carcinoma (FTC) accounts for 10 to 15% of differentiated thyroid cancers and often spreads hematogenously to bone or lung. Bone metastases, occurring in 2 to 13% of cases, significantly reduce survival and quality of life.
Arvind Krishnamurthy, Sree Subramaniyan, Sharada Bhavana, R. Krishna Kumar   +3 more
core   +1 more source